Gastrointestinal Cancer

Experts in gastroenterology share their approaches to first-line single-agent and combination TKI therapies for the treatment of advanced HCC.

Wasif M. Saif, MD, MBBS, discusses recommendations for germline testing in patients with pancreatic cancer.

Syma Iqbal, MD, discusses the emergence of checkpoint inhibitors in upper gastrointestinal cancers.

AGEN1181, a next-generation CTLA-4 inhibitor, exhibited clinical activity both as a monotherapy and in combination with balstilimab in heavily pretreated patients with advanced solid tumors.

Steven J. Cohen, MD, discusses the importance of obtaining an adequate tissue sample for molecular testing in gastrointestinal cancers.

Howard S. Hochster, MD, FACP, discusses treatment considerations for patients with HER2-positive gastric cancer.

Drs Sam Klempner, Nataliya V. Uboha, Daniel H. Ahn, and Manish A. Shah discuss recent data presented at ESMO 2021 for metastatic or locally advanced gastroesophageal and gastric adenocarcinomas.

Diane Reidy-Lagunes, MD, unpacked recent updates in neuroendocrine tumors.

Dr. Kalyan and Dr. Mouli discuss the importance of multidisciplinary care in hepatocellular carcinoma, data regarding real-world personalization treatment recommendations, and the benefits of decision-making analysis tools in the space.

This content was developed in collaboration with Servier Pharmaceuticals and Onc Live

Daneng Li, MD, discusses the interim analysis results of a phase 1 trial evaluating surufatinib in United States patients with neuroendocrine tumors.

Andrea Casadei Gardini, MD, presents the case of a 63-year-old man diagnosed with advanced HCC, and the panel reviews available first-line treatment options for patients with advanced HCC.

Gastroenterology experts discuss whether there a is a role for systemic therapy for the management of intermediate HCC.

The FDA granted an orphan drug designation to toripalimab for the treatment of patients with esophageal cancer.

Dr. Ku underscores key takeaways from the CheckMate649 and DESTINY-Gastric02 trials in gastric/GEJ cancer and highlights ongoing research that has the potential to further inform treatment selection and sequencing in the field

Experts in gastrointestinal cancers review recent updates and clinical implications from phase 3 trials presented at ESMO 2021 in metastatic esophageal squamous cell carcinoma (ESCC).

The combination of pembrolizumab (Keytruda) and irinotecan- or paclitaxel-based chemotherapy was not found to be effective in pretreated, biomarker-unselected patients with extrapulmonary poorly differentiated neuroendocrine carcinomas.

Patients with carcinoid syndrome reported improved symptoms following treatment with telotristat ethyl.

The combination of surufatinib and toripalimab demonstrated promising clinical activity with a manageable safety profile when used as second-line treatment for patients with advanced neuroendocrine carcinoma.

Surufatinib demonstrated strong antitumor activity along with a manageable safety profile in heavily treated US patients with progressive extrapancreatic neuroendocrine tumors or pancreatic NETs, according to interim phase 1 data.

Heloisa P. Soares, MD, PhD, discusses the standard of care in metastatic pancreatic cancer.

It is crucial to understand and interpret the results from the landmark clinical trials in the context of recent FDA approvals in gastroesophageal cancers.

The FDA has granted an orphan drug designation to LYT-200, a fully human IgG4 monoclonal antibody targeting galectin-9, for use as a potential therapeutic option for patients with pancreatic cancer.

Lanreotide autogel/depot administered at 120 mg every 28 days may be an appropriate treatment for patients with advanced bronchopulmonary neuroendocrine tumors.

Wasif M. Saif, MD, discusses the evolving role of PARP inhibitors and anticipated trends for research in pancreatic cancer.

Wasif M. Saif, MD, MBBS, discusses the rationale to utilize PARP inhibitors in BRCA-mutated pancreatic cancer.

The small molecule drug conjugate PEN-221 was generally well tolerated and elicited significant clinical benefit in patients with pretreated gastrointestinal neuroendocrine tumors.

Andrea Casadei Gardini, MD, and Stephen L. Chan, MD, examine the use of TACE and TARE-Y90 for the treatment of HCC.

Stephen L. Chan, MD, reviews the case of a 72-year-old woman with mild alcoholic cirrhosis and provides insight on the potential role of adjuvant and neoadjuvant therapy for the treatment of HCC.

Several breakthroughs in recent years have rapidly shifted the treatment landscape for advanced HCC.